Repaglinide

• Description :

  Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus[1].

• Product Name Alternative :

  AG-EE 623ZW

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Potassium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  Metabolism-sugar/lipid metabolism

• Field of Research :

  Metabolic Disease; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Repaglinide.html

• Concentration :

  10mM

• Purity :

  99.89

• Solubility :

  DMSO : ≥ 50 mg/mL

• Smiles :

  CC(C)C[C@H](NC(CC1=CC(OCC)=C(C(O)=O)C=C1)=O)C2=CC=CC=C2N3CCCCC3

• Molecular Formula :

  C27H36N2O4

• Molecular Weight :

  452.59

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus.Medicine (Baltimore) . 2018 Sep;97 (38) :e12476.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [135062-02-1]